A phase II trial of ZD1839 (Iressa™) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer
Authors:
- Wilson H. MillerWMWilson H. Miller
- 1 January 2005
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 23 (2) , 165-170
Abstract
Purpose: The epidermal growth factor receptor (EGFR) appears relevant in the pathogenesis and progression of colorectal cancer. After completing a phase I pharmacodynamic trial of ZD1839, we undertook a dose expansion trial to examine the antitumour efficacy and adverse effect profile of this agent in a homogeneous group of patients with metastatic colorectal cancer (CRC). Experimental design: Eligible patients with metastatic or recurrent CRC received ZD1839 750 mg daily by mouth. This dose was selected based on a phase I trial conducted by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Treatment was continued until unacceptable toxicity or disease progression. Results: Twenty-eight patients were enrolled at three NCIC CTG centers. Twenty-three patients had received prior chemotherapy; 12 patients had received three or more regimens. No objective responses were observed in 24 evaluable patients, although 8 patients had stable disease (median duration of 2.2 months). The most frequent drug related adverse events were diarrhea, rash and nausea. Eleven patients required dosing modification (hold or reduction), while 3 patients discontinued therapy because of toxicity. There were no treatment related deaths. Conclusions: ZD1839, when given at 750 mg/day to patients with pre-treated metastatic colorectal cancer, does not result in significant tumor regression.Keywords
This publication has 16 references indexed in Scilit:
- A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials GroupInvestigational New Drugs, 2005
- Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?2003
- A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.2002
- Epidermal growth factor receptor-targeted therapy in colorectal cancerSeminars in Oncology, 2002
- Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaSeminars in Oncology, 2002
- Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2000
- Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999